Regulatory

December 20, 2023

Affibody’s Licensee Rallybio Announces Preliminary Phase 1 MAD Data for RLYB116

Solna, Sweden, December 20, 2023. Affibody’s licensee Rallybio Corporation (Rallybio) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected...

Read more

Regulatory

November 27, 2023

Affibody’s Partner ACELYRIN Provides Update on Izokibep Clinical Development Program

Solna, Sweden, November 27, 2023. Affibody’s partner ACELYRIN, INC. (“ACELYRIN”) today provided an update on its izokibep clinical development program, including the ongoing global Phase 2b/3 trial in psoriatic...

Read more

News

November 13, 2023

Presentation at Amercian College of Rheumatology (ACR) Convergence 2023 of positive izokibep long-term data from Phase 2 study

Solna, Sweden, November 13, 2023. Affibody today announced that positive long-term data from a Phase 2 trial of izokibep in Psoriatic Arthritis (PsA) will be presented at the ACR...

Read more

News

November 8, 2023

Affibody’s Nomination Committee for the 2024 Annual General Meeting

Stockholm, Sweden, November 8, 2023. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2024 Annual General Meeting (AGM) to be held on May...

Read more

Regulatory

October 3, 2023

Affibody appoints Peter Zerhouni as CFO

Solna, Sweden, October 3, 2023. Affibody AB (“Affibody”) today announced that Peter Zerhouni has been appointed Chief Financial Officer (CFO) of the Company. Peter Zerhouni joined Affibody as Chief...

Read more

News

September 12, 2023

First Long-Term Clinical Study of Izokibep Published

Solna, Sweden, September 12, 2023. The first publication outlining phase 2 efficacy and safety results from a long-term study of izokibep, a small biological IL-17A inhibitor, is now available...

Read more

Regulatory

September 11, 2023

Affibody’s Partner ACELYRIN Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

• The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. • HiSCR75 did meet statistical significance at week 16...

Read more

News

September 3, 2023

Affibody’s Partner Rallybio Presents Phase 1 Results at the 29th International Complement Workshop (ICW 2023)

Solna, Sweden, September 3, 2023. Affibody’s partner Rallybio Corporation (Nasdaq: RLYB) today presented results from the Phase 1 first-in-human clinical study of RLYB116 as a poster at ICW 2023...

Read more

Regulatory

August 30, 2023

Data demonstrating that Affibody’s PET imaging agent ABY-025 can be used to predict therapeutic response will be presented at EANM

Solna, Sweden, August 30, 2023. Affibody AB (“Affibody”) today announced the presentation of data from patients in a clinical study of the PET imaging agent 68Ga-ABY-025 for non-invasive quantification...

Read more